Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.80 |
| ▸ | CDK2 | P24941 | 4/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.73 |
| ▸ | CDK7 | P50613 | 2/20 | 0.73 |
| ▸ | CCNH | P51946 | 2/20 | 0.73 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28461058 | 0.88 | CDK1 (0.78) | CDK1CDK2CSNK1A1CSNK1DCDK7 | |
| SCHEMBL28457283 | 0.87 | CDK1 (0.76) | CDK1CDK2CSNK1A1CSNK1DCDK7 | |
| SCHEMBL6821050 | 0.86 | CDK1 (0.79) | CDK1CDK2PPARDKDM4ENPC1 | |
| SCHEMBL31072387 | 0.85 | CDK1 (0.78) | CDK1CDK2CSNK1DKDM4ENPC1 | |
| SCHEMBL28771300 | 0.85 | CDK1 (0.76) | CDK1CDK2PPARGPPARDKDM4E | |
| SCHEMBL22789735 | 0.85 | CDK2 (1.00) | CDK1CDK2CSNK1A1CSNK1DCDK7 | |
| SCHEMBL1443862 | 0.85 | CDK1 (0.76) | CDK1CDK2CSNK1DKDM4ENPC1 | |
| SCHEMBL6820864 | 0.85 | CDK1 (0.76) | CDK1PPARGPPARDKDM4ENPC1 | |
| SCHEMBL1400442 | 0.84 | CDK1 (1.00) | CDK1CDK2CSNK1DCDK7KDM4E | |
| SCHEMBL1443458 | 0.83 | CDK1 (0.80) | CDK1CDK2PPARDKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752629-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752629-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| CN-110256436-B | Purines as Trk kinase inhibitors | 南京雷正医药科技有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10174031-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174031-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180009810-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180009810-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-01-11 | — | — | US | disclosed |
| US-9796714-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796714-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796714-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009810-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | CDK1 2530/4885CDK2 3024/4885CSNK1A1 610/4885 |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | CDK1 2530/4885CDK2 3024/4885CSNK1A1 610/4885 |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | CDK1 2530/4885CDK2 3024/4885CSNK1A1 610/4885 |
| US-10174031-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | CDK1 2530/4885CDK2 3024/4885CSNK1A1 610/4885 |
| US-10752629-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | CDK1 2530/4885CDK2 3024/4885CSNK1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.